Monitoring CIRM at 1 a.m.,

CIRM Director Ken Burtis of UC Davis is participating in today's meeting of the governing board of the California stem cell agency from a teleconference location in Japan. He said that his current time at his location is a little after 1 o'clock in the morning.

Briefing on Stem Cell Portfolio

The first order of business at today's meeting of the governing board of the California stem cell agency is a briefing on the agency's development portfolio. Ellen Feigal, senior vice president for research and development, is speaking.

California Stem Cell Directors Open Meeting

Directors of the $3 billion California stem cell this morning began their meeting in Burlingame, Ca., at 9:05 a.m. PDT. On the agenda is a $13 million grant application that has been rejected by agency reviewers and staff. The applicant, Eduardo Marban, director of the Heart Institute at Cedars-Sinai, has filed an appeal, contending that the review involved an unspecified conflict of interest. Also to be considered are proposals for $72 million for new grant rounds to advance research into the clinic.

Conflict of Interest Charge On California Stem Cell Agenda Today

The California Stem Cell Report will provide live coverage of today's daylong meeting in Burlingame, Ca., of the governing board of the $3 billion California stem cell agency.

On the agenda are $72 million worth of concept proposals aimed at speeding stem cell therapies into the clinic, along with an allegation that a conflict of interest was involved in a $13 million grant application.

The meeting begins at 9 a.m. PDT. For those who would like to listen in live via the Internet, the agenda contains instructions and information about how to see the Power Point presentations being used.

The public can also participate in the meeting, make statements and ask questions at teleconference locations in Japan, Los Angeles(2) and La Jolla. Specific locations are on the agenda.

Conflict of Interest Alleged: Cedars-Sinai Scientist Appeals Rejection of $13 Million for Heart Research

The director of the Cedars-Sinai Heart Institute today asked the governing board of the California stem cell agency to approve his application for $13 million for heart research, declaring that the agency's review of the proposal was tainted by a conflict of interest.

Eduardo Marban
Cedars-Sinai photo

In a letter, Eduardo Marban contested the findings of a CIRM staff review of the conflict allegations. He said,

“The initial review was tainted by conflict of interest concerns. The re-review was conducted by staff in a peremptory manner without the usual CIRM due process: no patient advocates were involved, no comparator grants were evaluated, and no formal review reports have been provided. Only a pithy, dismissive summary by CIRM staff has appeared, and that only yesterday.”

Marban's application was the subject of an article on the California Stem Cell Report yesterday, which discussed the lack of transparency in the agency's grant review process, particularly in relationship to conflicts of interest. The application was quietly removed from CIRM board consideration in December and has been placed on the board's agenda for action tomorrow in Burlingame, Ca.

The agency withheld Marban's name, the names of reviewers and the nature of the conflict charges. Marban did not go into specifics concerning the conflict in his letter today. We have emailed him, seeking details.

Marban has previously received $7 million for research from the agency. Capricor, a company he founded, has received $20 million. The company is scheduled to be highlighted in tomorrow's CIRM governing board meeting as one of its success stories.

In his letter, Marban noted his previous research along with the latest proposal and its clinical potential, an increasingly important consideration for the CIRM board. Marban wrote,

“The commercial potential of (the earlier funded product) has been validated by a collaborative/option agreement between Capricor (the company I founded to develop regenerative therapeutics) and Janssen, an arm of the pharmaceutical giant Johnson and Johnson. This represents the first time that 'big pharma' has partnered with a regenerative medicine biotech to develop a product.”

Marban also said,

“The present proposal (DYNAMIC) is ready to go into patients immediately; it is FDA and IRB approved. In fact, we have a list of 30+ patients who are waiting to be screened for enrollment, as soon as funds are available. These patients are ill, with a mortality exceeding that of many cancers. Indeed, several eligible patients have died in the interlude between the last ICOC meeting, when this proposal might have been funded, and the present.

“DYNAMIC would be the first study in the CIRM portfolio to target hard clinical endpoints (mortality and re-hospitalization) in a very high-risk population (that of advanced heart failure). The population to be studied is very different, and much sicker, than in the ALLSTAR trial.”

Cedar-Sinai's Marban Files Appeal on $13 Million Heart Research Application

Eduardo Marban of Cedars-Sinai today filed a public appeal on his application for $13 million for heart research from the California stem cell agency. The application is the subject of an investigation by the agency into allegations by Marban of a conflict of interest involving the grant review. We will have more details shortly.

California Stem Cell Agency Reviews Its Response to Blue Ribbon Recommendations for Major Changes

The outside counsel for the $3 billion California stem cell agency has revisited actions taken by the agency in the wake of the Institute of Medicine report that recommended sweeping changes to deal with conflicts of interest at the agency, its controversial dual executive arrangement and the fundamental nature of its governing board.

James Harrison of Remcho Johansen and Purcell of San Leandro, Ca., prepared a 21-page report, including attachments, as part of an earlier plan to examine actions by the board in response to the blue ribbon report by the IOM, which cost CIRM $700,000.

The CIRM board greeted the IOM study in 2012 with something less than enthusiasm(see here and here), but has taken some steps to deal at least partially with issues raised by the IOM. Last week the California Stem Cell Report asked the chairman of the study, Harold Shapiro, former president of Princeton University, for his take on Harrison's recap. Shapiro has not responded.

Harrison repeated the agency's contention that only perceived conflicts of interest exist at the agency. And he said the board's alteration of voting procedures appear “to have largely addressed the perception of conflict of interest.” However, most of the document was merely descriptive as opposed to an evaluation of the pros and cons of each agency response. Nor did he compare the CIRM's responses to each of the recommendations of the IOM.

 

Live Coverage of Tomorrow's California Stem Cell Board Meeting

The California Stem Cell Report will provide live coverage of tomorrow's daylong meeting in Burlingame, Ca., of the governing board of the $3 billion California stem cell agency.

On the agenda are $72 million worth of concept proposals aimed at speeding stem cell therapies into the clinic, along with proposed changes in the administration of grants involving hundreds of researchers.

The meeting begins at 9 a.m. PDT. For those who would like to listen in live via the Internet, the agenda contains instructions and information about how to see the Power Point presentations being used.

The public can also participate in the meeting, make statements and ask questions at teleconference locations in Japan, Los Angeles(2) and La Jolla. Specific locations are on the agenda.

The California Stem Cell Agency and Death by Power Point

One of the readers of the California Stem Cell Report this week sent along the following commentary as a result of Monday's item called “Critiquing the California Stem Cell Story: 'Continuums' vs. Cures.”

The reader is a researcher at a major California institution, who does not want to be otherwise identified. The scientist's comment focused on one of the host of Power Point presentations used by CIRM at last January's meeting of the Citizens Financial Accountability and Oversight Committee, the only state entity charged with overseeing the stem cell agency and its governing board. Here is the full text of the comment.

“You referred to the slide show as mind-numbing.  I might call it weird. 

“The title: 'Advancing Stem Cell Science, CIRM's scientific scope' 

“The first slide 'CIRM's vision and strategy'  No vision or strategy follows.

“The near last slide: 'what does CIRM want?' is the stunner.

“CIRM 'wants:' 

“Stem cell therapies -- Not just any therapy but those 'where the stem cell connection is strong.' And if the connection is weak? Say the disease path was identified in stem cells, and the drug for the path made separately or turns out to be a small molecule? Then what? CIRM won't fund it. A plan for development -- so what have they been doing for 10 years?

“CIRM wants to have a strong, 'major impact' -- Is this a vision, lament, or failure to hire the right publicist?

“CIRM wants diseases that already come with biomarkers and a good understanding of the pathophysiology, diseases that come with their own definitions of efficacy, so that clinical trials are easy to do. Heck, if we knew all that, then treatment development would be rational and easy; both NIH and industry money would and does fund it.

“CIRM wants proof of concept by 2017. Please give us a disease and intervention for which we can do a phase 2a study and show efficacy. 

“Finally, CIRM wants 'a strong, credible team with expertise ...' and executive ability.  Yes, as their regular pronouncements indicate, they lack credibility and expertise in many areas?"

Our take: Clearly the use of Power Point presentations at the CFAOC session did not have the desired effect, either on the audience at the time or on the scientist who sent the above commentary. However, that was only part of the problem at that meeting.

The California Stem Cell Report's comment about mind-numbing Power Point presentations was also aimed beyond last January's meeting to include CIRM's heavy reliance on such presentations, which too often substitute for nuanced, written explorations of the issues at hand. The presentations by their very nature are nothing more than outlines. Almost invariably they are simply read to the audience, as in the governing board of the agency. If the goal of the agency is to convince persons outside the agency of the virtues of its billions of dollars in spending, “death by Power Point” is not the way to do it. Like any tool, such presentations have a use. But they are not always the best tool for everything.

Changing or dropping Power Point presentations, however, will not guarantee that CIRM can make the sale on its programs. If it is going to avert financial death in 2017, when funds for new grants run out, it will have develop a pitch that connects viscerally as well as intellectually.   

Nine-year Veteran of California Stem Cell Agency Board Resigns

Marcy Feit, a longtime member of the governing board of the $3 billion California stem cell agency, has resigned from the position.

She gave no reason for her resignation in her Feb. 6 letter to Lt. Gov. Gavin Newsom. She was appointed by Lt. Gov. Cruz Bustamante in 2005, who heralded her for her work in improving health care for rural residents of California.

Marcy Feit
CIRM photo

In the letter, she said she was resigning as of Feb. 4, the same day she quit as CEO of ValleyCare Health Systems in Northern California. No reason has been given for her departure from ValleyCare, but since then a wave of cutbacks has been announced for the enterprise.

Feit had headed ValleyCare since 1997. She was one of the few minority women to head a California health care system and the only minority woman on the 29-member CIRM board. (She is a Latina.) She has been noted for her efforts to improve its fiscal operations and accounting procedures. Here is the full text of her letter to Newsom, who will appoint her successor. The letter was provided by CIRM at the request of the California Stem Cell Report.

“I write to inform you of my resignation as a member of the Independent Citizens Oversight Committee, the Governing Board of the California Institute for Regenerative Medicine, effective February 4, 2014. It has been my honor to serve the State of California as one of your appointees to CIRM’s Governing Board. I am extraordinarily proud of the progress we have made in establishing CIRM, developing strong ethical, medical, and scientific policies, and ensuring that Californians will have the opportunity to benefit from the important research that CIRM is funding.

“With your support and with the hard work of CIRM’s Board and staff, CIRM has become the largest funder of human embryonic stem cell research in the world. Dramatic findings have already emerged from CIRM-funded research and I am hopeful that this research will one day lead to therapies for Californians who suffer from chronic disease and injury. Thank you for the opportunity to serve.”

The $13 Million Matter of DR3-07201: Allegations of Conflict of Interest at the California Stem Cell Agency

In an unusual move last December, the California stem cell agency removed – with no public explanation – an application for $13 million from consideration by its governing board.

That application is now back before the board on Thursday and is almost certain to be rejected.

What is missing, however, are important specifics about the matter. They are cloaked by the agency's rules that conceal most of the CIRM grant review process, including the names of applicants along with the identities of reviewers and their economic and professional interests. Also shrouded are the details of any complaints about conflicts of interest as well as any other appeals.

Nonetheless, since the proposal was listed on the agenda of a public meeting of a state agency, it is known that it involves application DR3-07201. The unidentified applicant, according to a CIRM summary, sought $13 million for research into a treatment for heart failure, a therapy that is labeled by the applicant in all capital letters as “DYNAMIC.”

The agency's scientific reviewers last year recommended rejection of the request for funding. The agency's review summary said,

“The major serious criticism and flaw stems from the fact that the applicant is currently evaluating the same cellular product in a Phase 1/2 trial in a different subgroup of cardiac patients. Since the objectives of the proposed and currently enrolling trials are similar, reviewers agreed that the proposed Phase 1 trial does not add value and should be re-evaluated after completion and analysis of data from the current trial .”

No scientific score was released for the review but it was last on the list of all applications in this particular round. The agency usually lists the applications in order of their scores.

Following the removal of the application from the board agenda, the California Stem Cell Report in December inquired about the reason. Kevin McCormack, senior director of communications, replied via email,

“We received a last-minute appeal based on an alleged conflict of interest.  In order to allow time to review the claim, we deferred action.  We have done this previously, though I don’t have an exact count.”

When the application popped up on the agenda for this week's meeting, we inquired again, seeking more information. That was seven days ago.

The answer came in the form of a posting yesterday on the CIRM Web site of a one-page memo dated March 7 from Gil Sambrano, CIRM's associate director, review. In the note to the CIRM board, Sambrano said a conflict of interest allegation was raised by the applicant on the morning of Dec. 12, 2013, the day on which the application was to be considered. Sambrano said,

“The applicant alleged that the GWG (grant working group) review of the proposed project may have been 'tainted' by the 'perceived lack of objectivity' of one member of the GWG. There was no specific basis to support a financial, professional or personal conflict as defined in the GWG conflict of interest policy.”

Sambrano said the investigation into the complaint determined there was no violation of the agency's conflict of interest rules. He said,

“We found no evidence that the reviewer had any significant influence on the score or the recommendation. The reviewer was not an assigned reviewer and therefore did not contribute a written critique to the panel. Consistent with the recollection of the review chair and CIRM science officers in attendance, the discussion notes suggest that this reviewer did not provide any comment either in favor or against the proposal. The individual score given by the reviewer was very close to the mean score and thus did not contribute to the broad standard deviation.”

Sambrano continued,

“The applicant also submitted a request for reconsideration based on material new information. Although the applicant provided some information that is new, it did not directly address the main concern of reviewers and therefore did not provide adequate grounds for reconsideration. The request was denied.”

Sambrano said the agency took an additional step of seeking the opinion of two new expert reviewers and the chair of the grant review group. He said they did not find the new information “compelling.”

Reviewer Joyce Frey-Vasconcells was barred from participating in the review of the application, according to its CIRM review summary. Other reviewers in the round who could participate in assessing the application included Joy Cavagnaro, Raj Chopra, Derek J. Hei, Hassan Movahhed and Andrew Balber. Their names were listed on review summaries on other applications in the round where they had conflicts of interest, either professional or economic.

The applicant's appeal does not necessarily end with the CIRM staff decision. The applicant can appear before the board in public on Thursday and seek to overturn the action or ask for further investigation. It can also send material to the agency for delivery to all board members. 

As mentioned previously, the name of the applicant was withheld by the stem cell agency. But it could likely be discerned by a knowledgeable stem cell researcher based on information contained in the review summary. If the applicant would like to send both of its appeals to the California Stem Cell Report, we would be glad to carry their full text and any additional commentary that the applicant would like to make. Other applicants have done so in the past. The agency has no prohibition against such an action and actually has a term for it – self-disclosure.

Our take: The stem cell agency's appeal process ill serves the California public, grant applicants and CIRM itself. The $3 billion agency's reliance on secrecy only raises more questions about cronyism and unfairness, some of which have dogged CIRM since its inception. The recent flap over the $40 million genomics round is only the most recent example. Roughly 90 percent of all the cash handed out by CIRM has gone to institutions that are represented on its governing board, which sets the rules for the grant-making process and determines the nature of the grants. The board's conflicts are built in by Prop. 71, the measure that created the agency in 2004. The only genuine way to ameliorate the issue is with more transparency.

Critiquing the California Stem Cell Story: 'Continuums' vs. Cures

It was a genuine “where's the beef” session for California's nearly 10-year-old, $3 billion state stem cell agency.

A member of the only state body legally delegated to oversee the California Instititute of Regenerative Medicine (CIRM) and its governing board wanted an answer to a simple question: What cures has the agency produced as promised during the 2004 ballot campaign that created the state program?

The occasion was a meeting Jan. 22 in downtown Los Angeles of the Citizens Financial Accountability and Oversight Committee, a group headed by state controller John Chiang. It meets once a year to examine the activities of the agency.

Jim Lott
COPE photo

Jim Lott, a long-time member of the panel and an executive vice president of COPE Health Solutions of Los Angeles, was pressing CIRM Chairman Jonathan Thomas and Ellen Feigal, CIRM's senior vice president for research and development.

According to the transcript, Lott, who described himself as a “big supporter” of CIRM, said, 

“I think when many voted for this, they thought there were going to be some cures coming out of this effort. And my bias is I have a 13-year-old daughter who has a spinal cord injury, partial break. I'd like to go home and tell my wife that this did something to advance the medical therapy that will ultimately provide her with the opportunity to walk again. What can you tell me that we've done that's going to get my daughter out of her wheelchair sooner (rather) than later after all this money has been spent?”

Thomas and Feigal struggled at some length to give him satisfying answers to his question. 

It was a tough series of exchanges with Thomas and Feigal talking about “incremental” work and “continuums” along with unrealistic, high expectations raised by the 2004 campaign. Those expectations burden the agency's current efforts to find new funding for awards beyond 2017, when the cash runs out.

At one point, Lott said it would be a “hard sell” to get voters to back more funding. Thomas acknowledged that and said it is “not stuff that readily translates into good sound bites.”

“You don't have a good message,” Lott said, declaring that he raised the issue two years ago.

“You guys are not speaking to people in ways that they understand the value of what you are doing. And that bothers the heck out of me.”  

Here is an exchange from early in the meeting involving Feigal and Lott, who has spent 23 years in the California hospital industry.

Lott:

“What can we say we've done to advance to a cure or to cures? It's fine that we've got all -- we've contributed to all. What can you say that we've actually done? We don't really have any -- I'm going to just say this because it's a bias and I know it's a bias. We don't have any tangible specific and measurable results that I can point to.”

Ellen Feigal

Feigal:

“Actually –”

Lott:

“Tell me if I'm wrong and demonstrate it to me. I want to understand where the results are.”

Feigal:

“So I'm happy to tell you the results, but I guess the issue is the expectations. And when this was funded, it probably was an expectation that (if we) give them money and within a very, very, very short period of time, and frankly ten years is a relatively short period of time, and, as you may not know, the funding didn't start till 2006, but if you try -- we're trying to do things in a very accelerated way. The funding actually for the disease teams and strategic partnerships just started three years ago. Part of it is advancing....”

Feigal continued in that vein for a few more minutes. Lott then asked about CIRM's return on investment(ROI), which amounts to $6 billion that the state will have to pay to support the agency, including the interest on the money that was borrowed for grants.

Jonathan Thomas
CIRM photo

Thomas, a bond financier from Los Angeles, jumped in,

“The results are, do we have any cures? No, we don't have any cures, but the results are many. They're incremental, but they are all moving along a research continuum that any sort of drug therapy would follow.....”

Lott:

“Here's my problem. As you said earlier, and I agree with it completely, I think it's a question of expectations. I know when I voted for this, and I did vote for it, I had some expectations. And my expectations were (that) we were going to see something in terms of cures at the end of the rainbow after we spend $3 billion, whatever it is that we're spending here.

“So when I asked for an ROI -- and I do understand what you are trying to tell us. I do get it, but it's not translatable. It doesn't translate to the expectations that many of us voters had.”

Lott kept coming back to his essential question

“The point is if we did spend all this money, what did we
get for it?”

Thomas and Feigal, aided by their Power Point presentations, continued to talk about CIRM's partnerships, disease teams and funding mechanisms.

Thomas:

“So if we do go back for a subsequent bond measure, I think we will be able to tell a story that will make California proud of being on the cutting edge and having facilitated the acceleration of the research, which, as Ellen said --”

Lott:

“Not if you don't get beyond the marketing problem you got. I'm telling you, pal, I would have a hard time voting for it again."

Thomas:

“That's fair.”

Our take: The California stem cell agency is virtually unknown to most of the people of California, which is not an unusual situation for most state agencies. Since Thomas was elected chairman in 2011, however, it has vastly improved its communications efforts. Nonetheless, it has not fulfilled the campaign promises of cures and won't be able to do so in the next two years. It does have a story to tell, albeit one that does not fit with the mythology of magical stem cells. Telling that story is hindered by mind-numbing Power Point presentations, which are little more than outlines that would be better replaced by nuanced, written documents. The challenge for the agency is to present not only the dry numbers but package the key figures with information that will connect viscerally and persuade people of the virtues of CIRM. Packaging and sizzle are the watchwords, depending on the audience. Each group has different concerns that need to be researched in advance and then addressed in tailored presentations. Whether CIRM's efforts so far have been worth $6 billion remains to be determined, but it is clear that it has not yet made its best case.

Japanese and California Stem Cell Affairs: An Opportunity to Make a Connection

This baby is a spin-off in Japan from CIRM-financed research.  Kazuhiro Kawamura 

of the St. Mariana School of Medicine delivered the child, which he is holding.

 (Kawamura photo)

Scientists and other stem cell fanciers in Japan will have their first chance this Thursday to take part in a meeting of the governing board of the $3 billion California stem cell agency.

Ken Burtis
UC Davis photo

That's because one of the board members, Ken Burtis of UC Davis, is in Nara, Japan, for a visit on the day of the meeting in Burlingame, Ca. He will be linked to the session via a telephone connection. It will be a two-way hookup that the public can use to participate, a requirement of California state law.

Stem cells are a hot scientific and commercial topic in Japan. According to an article last November in the Japan Times, the country's regenerative medicine market is expected to climb to $15.85 billion in 2030, up from $260 million in 2012. Japan is also the home of the induced pluripotent stem cell, which was first produced there.

Burtis is a professor of genetics and provost at UC Davis. It was not immediately known whether his visit to Japan involved UC Davis, the stem cell agency or was personal.

Burtis' access to the stem cell meeting, which includes a lengthy briefing on the agency's development portfolio, will be from the Hotel Nikko in Nara. Interested parties will be able to participate from the room in which Burtis is monitoring the meeting. However, the meeting agenda does not specify a room number. That will have to be obtained by emailing the stem cell agency at info@cirm.ca.gov. It is best to do that well in advance of the meeting.

This week's meeting has nothing specific on the agenda related to Japanese stem cell affairs, but stem cell research is a global matter. Researchers and others in Japan may well learn something new, particularly from the briefing on the agency's portfolio, and will have an opportunity to pose questions. Additionally, the board will be considering $72 million in "concept" proposals to speed commercialization of stem cell research, which could well be of interest to Japanese stem cell researchers and biotech firms even if they are not eligible for awards.

The California stem cell agency, which is known as CIRM, has also had a collaborative arrangement with Japan Science and Technology Agency since 2008.

Masaya Nakamura
Keio photo

Aileen Anderson
UCI photo

The agreement has resulted in one collaborative funding project involving Aileen Anderson of UC Irvine and Masaya Nakamura of Keio University. Anderson has received $1.3 million from CIRM, which did not announce the amount of funding that Japan provided to Nakamura.

Aaron Hsueh
AFP photo

Aaron Hsueh of Stanford received $2 million from CIRM for work that later led to a novel way of treating some forms of infertility and further work with Japanese researchers. One child has been born in Japan using the techninque. Kazuhiro Kawamura (pictured at the top of this item) and others at St. Mariana University School of Medicine were involved in that effort, which was not funded by CIRM. Another woman was pregnant as of October 2013. No information about the result of that pregnancy was immediately available. (See here and here.)

(Editor's note: This item has been altered slightly from the original version to make it clearer what is on the agenda this Thursday and its relationship to Japan. The headline has been reworded. No information has been dropped.) 

Science and Blogging: A STAP Stem Cell Case Study

It is a story that has to do with high priests, cloistered discussions and the glacial pace of scientific research.

The tale involves George Daley of Harvard, Paul Knoepfler of UC Davis and Japanese and Massachusetts researchers who say they can create STAP cells with an acid bath.

Let's start with the acid bath research, which rocked the stem cell world a few weeks ago. The apparently simple method of generating cells surprised nearly all researchers, some of whom expressed skepticism.

Paul Knoepfler

Paul Knoepfler is one scientist whose analysis of the research was available for the world to see on his blog, ipscell.com. Knoepfler is also one of the few stem cell researchers to blog about their field, a matter that troubles some scientists.

In recent weeks, Knoepfler has carried polls about the STAP research, interviewed two of the researchers involved and encouraged efforts at replicating the findings., among other things. He has even drawn some tentative conclusions. All of which does not necessarily meet with the approval of George Daley. He was quoted in the Boston Globe yesterday by Carolyn Johnson as saying,

“I am concerned about the rush to use blogging and social media to report early experience with a complex biological experiment. Most scientific experiments take time and many replications to work confidently, and early reporting may reflect a negative bias.” 

Within hours Knoepfler, whose blogging on STAP has drawn widespread attention, took a politely different view about the use of the social media and science. He wrote that social media has had a "strongly positive impact" on the discussion of the STAP cell research. He said it has facilitated international communication in a way that the traditional venues could not have done. Knoepfler wrote,

 “Journals are far too slow and frankly just too politically correct.”

He continued,

 “I suspect that in (a) hypothetical social media-less reality there would be no Nature or RIKEN investigations going on to help clarify certain elements of the STAP situation. I’m convinced there would also have been no detailed STAP protocol put out there in the public domain as we saw pop up yesterday. The two STAP Nature papers would also almost certainly still be behind pay walls instead of openly available via my request to Nature to make them that way. 

“Yet at the same time dozens of labs would still be trying STAP-related experiments relatively in the dark and unconnected to each other, wasting time, reagents, and other resources. For a long time, in that hypothetical scenario, only Nature, RIKEN, and the STAP authors themselves would have entirely controlled the flow of information about STAP cells. With all due respect I don’t think that would have benefited the stem cell field.”

Jeanne Loring

As of this writing, Knoepfler's item on the use of social media has drawn six comments. One came from Jeanne Loring, head of the Scripps stem cell program. She said,

“I think this was a successful experiment – a lab meeting without borders. Imagine that a STAP researcher was reporting her results at a lab meeting – you and the hundreds of others in your worldwide lab would be obligated to give critical feedback. The authors shouldn’t feel any more personally attacked than they would if their colleagues in the meeting were criticizing their work. This should be familiar to everyone who works in a lab.”

Our take: Every major enterprise, but perhaps more so in science, contains its high priests, individuals who control discussion and formally or informally lay down rules. Then there are institutions and vested interests that collaborate on setting the standards, such as permitting discussions in only certain cloistered venues, away from the untidiness that might involve the public or those deemed to be ill-informed or whose views are unwelcome. Along with that comes inertia, an unwillingness to change and resistance to new techniques. All of which leads to glacially slow dissemination of information that could speed research and development of therapies that could save lives.

Michael Eisen

Michael Eisen, a scientist at UC Berkeley, weighs in on this topic regularly. In a blog item September 2012, he noted that most papers that had been submitted 10 months earlier to journals were still languishing on some editor's or reviewer's desk.

“Consider that most papers submitted to journals last November 26th have still not been published. That’s not a random date – it happens to be the day NASA launched an Atlas rocket carrying the Mars Scientific Laboratory from Cape Canaveral.

“While, on Earth, scientific papers were languishing in editorial purgatory and peer review, bouncing back and forth while authors attempted to cater to some reviewer’s whim, maybe went to another journal, and then sat around in production for months while the awaited online publication, an SUV-sized robot made its way to another planet, landed with pinpoint accuracy on the surface and started beaming back pictures. NASA 1. Publishing 0.”

Use of the social media is unsettling to many scientists. Nonetheless, it is a fact of life. Its use will inevitably grow. Like newspapers, the reach and role of the journals are diminishing. The only question is how fast. For researchers to turn their back now on a key information sharing tool such as social media would be like rejecting the microscope because of wariness about new-fangled gizmos and their reliability.

There is another bottom line on all this: Money. One of the reasons for the financial plight of the NIH and research funding is the lack of widespread, public enthusiasm for research. If research funding had the kind of constituency that Social Security and Medicare have, there would be few problems with cash for scientific grants. While research funding is unlikely to ever achieve that sort of support, it can improve its public standing by artful use of social media. Mastering those techniques should be high on the agenda of every researcher in the country.

Craig Venter's "Road to the Cure" Stem Cell Venture

Craig Venter aboard his research yacht in 2004.
Sidney Morning Herald/Dallas Kilponen photo

Craig Venter, the international genomics superstar, is staking out a claim on stem cell turf.

The move comes with the formation of Human Longevity, Inc.(HLI), Venter's new company in the La Jolla, Ca., area.

Venter kicked off the enterprise this week with the announcement that it had $70 million in backing. The company press release said the firm is a “a genomics and cell therapy–based diagnostic and therapeutic company focused on extending the healthy, high performance human life span.''

Most of the news coverage concentrated on genomics. But the firm's press release also said,

“The company will be embarking on an ambitious multi-pronged effort utilizing stem cell therapy advances to enhance and improve the healthy life span. HLI's work is premised on the theory that as the human body ages many biological changes occur, including substantial changes and degradation to the genome of the differentiated, specialized cells found in all body tissues. There is also a depletion and degradation of healthy regenerative stem cell populations in the body over time. HLI will monitor the genomic changes which occur during stem cell differentiation, normal aging, and in association with the onset of disease.

"'The global market for healthy human longevity is enormous with total healthcare expenditures in those 65 and older running well over $7 trillion,' said Dr. (Bob) Hariri. 'We believe that HLI's unique science and technology, along with our business leadership, will positively impact the healthcare market with novel diagnostics and therapeutics.'"

Bob Hariri
HLI photo

Hariri. the former CEO of Celgene Cellular Therapeutics, is vice chairman and co-founder of the new firm, which is located on a street called “Road to the Cure.”

Writing on Biopolitical Times, Pete Shanks of the Center for Genetics and Society in Berkeley picked up part of the conference call earlier this week announcing the company. Shanks said, .

"Asked on this conference call if HLI would be in touch with the new Sanford Stem Cell Clinical Center (at UC San Diego), Venter blandly noted that Larry Goldstein, who heads the center, is on the HLI advisory board. (Peter) Diamandis added:

'Stay tuned for more announcements on the stem cell side.'"

Diamandis is a co-founder of the firm and CEO of the X Prize Foundation. The Sanford stem cell center was funded with $100 million last fall from billionaire Denny Sanford. Goldstein has received $21 million in funding from the California stem cell agency. Three other representatives from UC San Diego are on the HLI scientific advisory board including David Brenner, a longtime member of the governing board of the California stem cell agency.

Venter was a featured speaker at a California stem cell agency governing board meeting in 2012. The J. Craig Venter Institute is a partner in the $40 million genomics stem cell award made by the agency to a team led by Stanford in January during a controversial award process.

Sangamo and the California Stem Cell Agency: Good News for Both

Sangamo Biosciences is one of the California stem cell agency award recipients that is again surfacing in the news in a way that could ultimately burnish the reputation of the $3 billion research enterprise.

Sangamo, a publicly traded company based in Richmond, Ca., popped up in a story in the New York Times dealing with the search for a cure for AIDS involving researchers at the University of Pennsylvania.

Sangamo is also involved in another AIDS research project financed by the stem cell agency at the City of Hope and USC.  The company produces a gene-editing tool and its stock price is soaring. 

The Times story by Denise Grady reported on the phase one clinical trial at the University of Pennsylvania. She wrote,

“The idea of genetically altering people’s cells to make them resist the virus that causes AIDS may seem like a pipe dream, but a new report suggests it can be done.

“The research involves the first use in humans of 'gene editing,' a treatment that zeros in on a particular gene and disables it.”

We asked the stem cell agency how the trial fits with the work financed by CIRM. Kevin McCormack, senior director for communications, replied,

“On first glance it looks as if this works with the CD4 t-cells while the work we are financing focuses on a similar approach but perhaps the best explanation of the difference comes from this section of the original application from John Zaia's team at City of Hope that is partnering with Sangamo. 

“'Recently, ZFNs have been shown to inactivate CCR5 in primary human CD4 T cells, allowing them to preferentially survive and expand in the presence of HIV. A human clinical trial evaluating this approach is on-going, in which patient T cells are re-infused after ZFN-treatment to block CCR5 expression and possibly provide an HIV-resistant reservoir of CD4 T cells (THIS IS THE PIECE IN THE NY TIMES ARTICLE). The CIRM Disease Team proposes an approach to modify a patient’s own HSC to circumvent the need to find matched donors that carry the Δ32 CCR5 mutation and yet provide a renewable and long-lasting source of HIV-resistant cells.'”

Sangamo's stock has climbed dramatically this year. On Jan. 9,  based on news of an investment in the company by Biogen Idec, Sangamo opened at $15.70, rose to $19.12 and closed at $18.88. The volume of shares traded was 10.4 million. The average volume of trading over has been well less than 1 million for most of the last 12 months.

Today the stock closed at $22.96, up from $18.92 at the Tuesday close, the day before the clinical trial news surfaced. Volume hit 11 million shares. Sangamo's 52-week low is $6.86.  

$145 Million Bond Sale Next Month for California Stem Cell Agency

The state of California will offer up $1.6 billion in general obligation bonds next week but none will be for the state stem cell agency.

The next round of bond funding involving the agency is scheduled for April 22 with $145 million slated to go for stem cell financing, Tom Dresslar of the state treasurer's office told the California Stem Cell Report.

The $3 billion agency is financed through state borrowing (bonds), which roughly doubles the cost of its activities because of the interest expense on the bonds. The state currently provides cash to the agency via short-term debt (commercial paper). Then the state sells taxable bonds to repay the short-term debt.

During the 2004 ballot campaign for Prop. 71, the public was led to believe that the agency would be financed with non-taxable bonds, which would have meant lower borrowing costs for the state to the tune of hundreds of millions of dollars.

In 2007, Bernadette Tansey, then of the San Francisco Chronicle, reported that Robert Klein, head of the Prop. 71 campaign and first chairman of the stem cell agency, knew that taxable bonds were likely to be required but did not disclose that fact to the public.

$72 Million for Commercial Stem Cell Therapies?

The $3 billion California stem cell agency next week is likely to move to pump about 12 percent of its remaining, dwindling cash into business-friendly efforts to develop commercial therapies.

Coming before the agency's governing board on March 13 are two “concept” proposals for grant and loan programs totaling $72 million that are in line with CIRM's drive towards the marketplace and fulfillment of the promises of the 2004 ballot campaign that created the agency.

The proposals are coming from the agency's staff and fit with the strategic direction of the board. Such proposals have almost never been rejected in the past. But the board has demonstrated some fiscal concern in recent months as its uncommitted funds have shrunk to roughly $600 million, according an estimate presented by agency Chairman Jonathan Thomas in late January. The agency is scheduled to run out of cash for new awards in 2017.

The largest new proposal before the board would provide up to $40 million for four or five preclinical development awards. They would be aimed at development activities prior to a phase one clinical trial and at helping to attract future funding. Businesses and non-profits would eligible with businesses possibly taking a forgivable loan.

The second proposal would provide up to $32 million for possibly three awards in the agency's strategic partnership program ranging from $10 million to $12 million. The objective would be completion of a phase one or phase two clinical trial within three years. Matching funding would be required. Both businesses and non-profits would be eligible with forgivable loans a possibility for businesses.

If potential competitors for the awards are interested in shaping the direction of the proposals, next week's meeting in Burlingame is the time to appear before the board. The next step is posting a request for applications, scheduled for April and May. Board action on applications would come early next year.

$40 Million California Genomics Award: Missing Names of Conflicted Reviewers Disclosed

When the governing board of the California stem cell agency last month considered proposals for a $40 million genomics stem cell center, it failed to disclose the names of the grant reviewers who were barred from reviewing the applications because of conflicts of interest.

Normally, the names are reported to the public when the $3 billion agency posts summaries of the reviews of applications – prior to consideration of the proposals by the agency's board.

The departure from the agency's normal grant-making procedures is not the first in the genomics round, which is the subject of an internal examination by the agency that includes the board's outside counsel, James Harrison of Remcho Johansen and Purcell of San Leandro, Ca. Allegations of conflicts of interest and complaints about the role of CIRM President Alan Trounson, score manipulation, irregularities and unfairness have been raised.

It is unlikely that the normal disclosure of conflicted reviewers' names would have affected the outcome of the genomic awards at the governing board meeting Jan. 29. However, if questions had been raised at the public board meeting about the absence of the names, concerns about the closed-door review process may well have been elevated, given the earlier conflict-of-interest violation involving reviewer Lee Hood.  

The names of the reviewers with conflicts were added to the review summaries this week following an inquiry Monday by the California Stem Cell Report, which sought to double-check the apparent fact that no reviewers were in conflict since none were listed as recused.

Kevin McCormack, senior director for communications for the agency, replied,

“There were some conflicts of interest with the genomics review but apparently there is a bug in our data system, which is why they aren't showing up. We're going to fix that so thanks for bringing it to our attention.”

Here are the names of the reviewers now listed on the CIRM review summaries as being recused and the four applications involved. The four were recommended for funding by reviewers.

Stanford-Salk's winning application, Richard Gibbs, Maynard Olson; UCLA, Bradley Bernstein, Richard Gibbs, Aarno Palotie, Barry Rosen; Scripps-Illumina, Maynard Olson, Martin Pera, Jared Roach; UC San Francisco–UC Berkeley, none.

Robert Klein, the California Stem Cell Agency and a $5 Billion Proposal

The California stem cell agency last week put a little distance between it and its former chairman, Robert Klein, who is currently touting a new, $5 billion bond measure to rescue the agency from its financial demise.

The agency's comments came in response to a news story about comments that Klein, a Palo Alto real estate investment banker, made at a symposium at UC San Diego's Moores Cancer Center.

Bradley Fikes of the San Diego U-T wrote a story on Feb. 20 about the appearance that was headlined “$5B initiative proposed for stem cell research.” Fikes said,

“Supporters of California’s multibillion-dollar stem cell program plan to ask for $5 billion more to bring the fruits of research to patients.”

Fikes reported that Klein said “he’s going to be talking with California voters about the proposal. If the public seems receptive, backers will work to get an initiative on the 2016 ballot to extend funding for the California Institute for Regenerative Medicine(CIRM).”

Klein, who left the agency nearly three years ago, has talked for several years about another bond measure on top of the $3 billion, 10-year borrowing effort approved by voters for CIRM in 2004. His latest statements are the first in which he has publicly specified a figure.

In the wake of Fikes' story, the California Stem Cell Report asked the agency for a comment on Klein's remarks and his current role at the agency. Kevin McCormack, senior director for communications, replied Friday,

“Bob has been talking about a new bond initiative for a couple of years now so this is not altogether surprising. However, our focus remains where it always is, on our mission and the progress that is being made by CIRM-funded researchers to find new treatments and cures for patients, and we are continuing to explore avenues to sustain that progress.”

Currently the agency is looking into some sort of public-private arrangement that could finance its operations beyond 2017, when funds will run out for new awards. The 2004 initiative limited the agency's $3 billion bond authorization to only 10 years. CIRM is counting the 10 years as beginning from the date the first bonds were sold.

So far, the assumed public contribution for CIRM's future is a fraction of what Klein is touting – only $200 million.

Klein's public appearances around the state talking up another bond measure raise questions about how his efforts fit with the planning of the agency itself and the financial explorations of the current chairman, Jonathan Thomas, a Los Angeles bond financier, and other members of the CIRM board. California policy makers, potential wealthy donors, foundations and corporations may well be confused about whether Klein is speaking for the agency either directly or indirectly.

Given McCormack's carefully worded statement, it is reasonable to assume that CIRM is not entirely enthusiastic about Klein's bond measure pronouncements.

Additionally, premature discussion of more state borrowing, which has been criticized by Gov. Jerry Brown, could lead to a hardening of positions at an early stage. In 2011, when Klein initially broached another bond issue, the San Jose Mercury News said in an editorial,

“What planet are these guys from?....Going back for more would make no sense regardless of the economy....”